Squarepoint
PRAX icon

Squarepoint’s Praxis Precision Medicines PRAX Stock Holding History

Squarepoint’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.9M Buy
+9,000
New +$2.78M ﹤0.01% 1913

Other funds holding PRAX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Squarepoint's PRAX Position: Q1 2026 in Review

Squarepoint increased its Praxis Precision Medicines (PRAX) stake by 6.3% in Q1 2026, buying an estimated $37.1K and bringing the position to 2,010 shares worth $648K. The position accounts for ﹤0.01% of the portfolio, ranked #3125.

Squarepoint first reported a position in PRAX in Q2 2021 and has held it in 11 quarters since. The position peaked at $843K in Q3 2024. 289 funds tracked by Wall St. Rank hold PRAX as of Q1 2026.

  • Squarepoint held 2,010 shares of Praxis Precision Medicines worth $648K as of Q1 2026.
  • Squarepoint bought 120 Praxis Precision Medicines shares in Q1 2026, an estimated $37.1K.
  • Praxis Precision Medicines made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3125 holding.
  • Squarepoint first reported a position in Praxis Precision Medicines in Q2 2021 and has held it in 11 quarters since.
  • Squarepoint's Praxis Precision Medicines position peaked at $843K in Q3 2024.
  • 289 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.